<DOC>
	<DOC>NCT01594281</DOC>
	<brief_summary>This study will assess the efficacy and safety of Ranibizumab alone or in combination with laser treatment vs. laser treatment alone in Proliferative Diabetic Retinopathy. Efficacy will be primarily measured by the change of area of neovascularizations as measured by Fluorescein Angiography at month 12 (difference to baseline value).</brief_summary>
	<brief_title>Multicenter 12 Months Clinical Study to Evaluate Efficacy and Safety of Ranibizumab Alone or in Combination With Laser Photocoagulation vs. Laser Photocoagulation Alone in Proliferative Diabetic Retinopathy (PRIDE)</brief_title>
	<detailed_description />
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Proliferative Diabetic Retinopathy BCVA ≥ 20 ETDRS letters Diabetes mellitus with HbA1c ≤ 12% (=107 mmol/mol) Proliferative vitreoretinopathy Clinically significant macular edema (CSME) Clinically non significant macular edema likely to develop to CSME NVD ≥ 2 DA or multiple NVE with a combined area of ≥ 2 DA involving the macula Vitreous hemorrhage Vitreomacular traction Previous scattered PRP treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Panretinal photocoagulation</keyword>
	<keyword>Ranibizumab</keyword>
</DOC>